Nursing Elites

1. A male patient is being treated with sildenafil (Viagra) for erectile dysfunction. What condition would contraindicate the use of this medication?

• A. Peptic ulcer disease
• B. History of myocardial infarction
• C. Recent use of antihypertensive medications
• D. Use of nitrates

Correct answer: D

Rationale: The correct answer is D: Use of nitrates. Sildenafil (Viagra) is contraindicated in patients taking nitrates due to the risk of severe hypotension. Nitrates and sildenafil both cause vasodilation, and the combination can lead to a dangerous drop in blood pressure. Choice A, peptic ulcer disease, is not a contraindication for sildenafil use. Choice B, a history of myocardial infarction, is not a contraindication unless the patient is also taking nitrates. Choice C, recent use of antihypertensive medications, is not a contraindication but requires caution as the combination can lead to additive effects lowering blood pressure.

2. A male patient receiving androgen therapy is concerned about the risk of prostate cancer. What should the nurse explain about this risk?

• A. Finasteride has been shown to lower the risk of developing prostate cancer.
• B. Finasteride does not affect the risk of prostate cancer, so regular screening is unnecessary.
• C. Finasteride may increase the risk of developing prostate cancer, so regular screenings are recommended.
• D. Finasteride has no effect on the risk of prostate cancer, so regular screenings are unnecessary.

Correct answer: A

Rationale: The correct answer is A. Finasteride has been shown to lower the risk of developing prostate cancer. However, regular screenings are still recommended to monitor for any potential issues. Choice B is incorrect because finasteride has been associated with a decreased risk of prostate cancer, making regular screenings important. Choice C is incorrect as finasteride is not known to increase the risk of developing prostate cancer. Choice D is incorrect as finasteride has shown a protective effect against prostate cancer, but regular screenings are still necessary to ensure early detection and monitoring.

3. Which type of lymphocyte recognizes and eliminates virus-infected cells and cancerous cells?

• A. Neutrophils
• B. Macrophages
• C. Natural killer cells
• D. Langerhans cells

Correct answer: C

Rationale: Natural killer cells are a type of lymphocyte that plays a crucial role in recognizing and eliminating virus-infected cells and cancerous cells. Neutrophils (Choice A) are a type of white blood cell involved in fighting infections, mainly through phagocytosis. Macrophages (Choice B) are another type of white blood cell that engulfs and digests cellular debris and pathogens. Langerhans cells (Choice D) are a type of dendritic cell found in the skin and mucosa, primarily involved in antigen presentation.

4. What lab results would be noted in a client with leukocytosis?

• A. Increased white blood cell count
• B. Increased platelet count
• C. Decreased white blood cell count
• D. Decreased platelet count

Correct answer: A

Rationale: Leukocytosis is a condition characterized by an elevated white blood cell count, typically in response to infection or inflammation. Therefore, the correct answer is an increased white blood cell count (Choice A). Increased platelet count (Choice B) is not a typical finding in leukocytosis. Choices C and D, decreased white blood cell count and decreased platelet count respectively, are opposite to what would be expected in leukocytosis and are therefore incorrect.

5. A patient has been diagnosed with cytomegalovirus (CMV). Which of the following drugs would be ineffective in the treatment of this disease?

• A. Ribavirin (Rebetol)
• B. Ganciclovir (Cytovene) IV
• C. Foscarnet (Foscavir) IV
• D. Valganciclovir hydrochloride (Valcyte)

Correct answer: A

Rationale: The correct answer is A, Ribavirin (Rebetol). Ribavirin is not effective against CMV. Choice B, Ganciclovir (Cytovene) IV, is a common treatment for CMV as it inhibits viral DNA synthesis. Choice C, Foscarnet (Foscavir) IV, is also used for CMV infections by blocking viral DNA polymerase. Choice D, Valganciclovir hydrochloride (Valcyte), is a prodrug of Ganciclovir and is effective against CMV. Therefore, Ribavirin is the drug that would be ineffective in treating CMV.

Similar Questions